Letter to the Editor: Obesity as a risk factor for greater severity of COVID-19 in patients with metabolic associated fatty liver disease

Metabolism. 2020 Jul:108:154244. doi: 10.1016/j.metabol.2020.154244. Epub 2020 Apr 19.

¹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
² Department of Gastroenterology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
³ Department of Critical Care Medicine, Wenzhou Central Hospital, Wenzhou, China.
⁴ Department of Infectious Diseases, Ruian People's Hospital, Wenzhou, China.
⁵ Department of Radiology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁶ Department of Nephrology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁷ Department of Endocrinology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
⁸ Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, Sydney, Australia. Electronic address: jacob.george@sydney.edu.au.
⁹ MAFLD Research Center, Department of Hepatology, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China; Institute of Hepatology, Wenzhou Medical University, Wenzhou, China; Key Laboratory of Diagnosis and Treatment for The Development of Chronic Liver Disease in Zhejiang Province, Wenzhou, China. Electronic address: zhengmh@wmu.edu.cn.

No abstract available

Keywords: COVID-19; MAFLD; Obesity; SARS-CoV-2.

Publication types